OmniAb Inc
OABI1.660USD
+0.040+2.47%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
203.68MValor de mercado
PerdaP/L TTM
Mais detalhes de OmniAb Inc Empresa
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Informações da empresa
Código da empresaOABI
Nome da EmpresaOmniAb Inc
Data de listagemOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Número de funcionários114
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 09
Endereço5980 Horton Street
CidadeEMERYVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94608
Telefone15102507800
Sitehttps://www.omniab.com/
Código da empresaOABI
Data de listagemOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
Distribuição de ações
Atualizado em: seg, 8 de set
Atualizado em: seg, 8 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Avista Capital Holdings, LP
12.89%
Whitefort Capital Management, LP
8.35%
Ash X LP
6.74%
BlackRock Institutional Trust Company, N.A.
5.16%
The Vanguard Group, Inc.
4.29%
Outro
62.57%
Investidores
Investidores
Proporção
Avista Capital Holdings, LP
12.89%
Whitefort Capital Management, LP
8.35%
Ash X LP
6.74%
BlackRock Institutional Trust Company, N.A.
5.16%
The Vanguard Group, Inc.
4.29%
Outro
62.57%
Tipos de investidores
Investidores
Proporção
Investment Advisor
16.49%
Hedge Fund
14.30%
Investment Advisor/Hedge Fund
12.94%
Private Equity
12.89%
Corporation
8.21%
Individual Investor
6.67%
Research Firm
1.02%
Pension Fund
0.14%
Venture Capital
0.11%
Outro
27.24%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
348
92.68M
75.53%
-5.84M
2025Q1
359
87.33M
71.43%
-8.58M
2024Q4
365
89.85M
74.79%
-8.38M
2024Q3
394
90.25M
75.21%
-25.05M
2024Q2
389
89.07M
76.08%
-29.09M
2024Q1
378
93.24M
79.93%
-23.55M
2023Q4
374
92.06M
79.14%
-28.03M
2023Q3
352
92.71M
80.23%
-26.22M
2023Q2
337
91.30M
79.07%
-24.17M
2023Q1
319
89.47M
77.82%
-24.53M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Avista Capital Holdings, LP
15.82M
12.93%
--
--
Sep 30, 2024
Whitefort Capital Management, LP
7.31M
5.98%
+3.40M
+86.81%
May 30, 2025
Ash X LP
1.09M
0.89%
+1.09M
--
Jun 12, 2025
BlackRock Institutional Trust Company, N.A.
6.46M
5.28%
+62.83K
+0.98%
Mar 31, 2025
The Vanguard Group, Inc.
5.18M
4.23%
+142.26K
+2.82%
Mar 31, 2025
Foehr (Matthew W)
3.80M
3.1%
-13.61K
-0.36%
Apr 23, 2025
Dimensional Fund Advisors, L.P.
3.13M
2.56%
+106.04K
+3.50%
Mar 31, 2025
Higgins (John L)
2.85M
2.33%
+20.00K
+0.71%
Jun 17, 2025
Rice Hall James & Associates, LLC
2.58M
2.11%
-68.23K
-2.58%
Mar 31, 2025
Private Management Group, Inc.
2.53M
2.07%
+296.71K
+13.29%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
iShares Morningstar Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
Dimensional US Core Equity 1 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
WisdomTree US SmallCap Fund
0%
iShares Genomics Immunology and Healthcare ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Fidelity Small-Mid Multifactor ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Ver Mais
iShares Morningstar Small-Cap ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
iShares Morningstar Small-Cap Value ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
WisdomTree US SmallCap Fund
Proporção0%
iShares Genomics Immunology and Healthcare ETF
Proporção0%
Fidelity MSCI Health Care Index ETF
Proporção0%
Fidelity Small-Mid Multifactor ETF
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
